Kala Pharmaceuticals Inc expected to post a loss of 43  cents a share - Earnings Preview

KALA BIO

09/08/2022 19:33

* Kala Pharmaceuticals Inc  KALA.OQ   KALA.O  is expected
to show
a fall in quarterly revenue when it reports  results on August
11. 
    * The Arlington Massachusetts-based  company is expected to
report
 a 33.7% decrease in revenue to $2.022 million from $3.05
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Kala
Pharmaceuticals Inc
is for a loss of 43 cents per share. For the same quarter last
year, the company reported a loss of 57 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kala
Pharmaceuticals Inc is $2.5​, above​ its last closing price
of $0.35. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.36       -0.36      -0.45     Missed  -25.9
 Dec. 31 2022  -0.44       -0.41      -0.68     Missed  -67.2
 Sep. 30 2021  -0.43       -0.43      -0.43     Met     0​
 Jun. 30 2021  -0.45       -0.44      -0.57     Missed  -29.5
 ​​Mar.        -0.47       -0.68      -0.49     Beat    28.4
 31 2021                                                
 Dec. 31 2020  -0.48       -0.46      -0.55     Missed  -20​
 Sep. 30 2020  -0.43       -0.44      -0.50     Missed  -12.8
 Jun. 30 2020  -0.42       -0.41      -0.42     Missed  -1.7
 This summary was machine generated August 9 at 18:32 GMT.  All
figures in US dollars  unless otherwise stated